Table 2 Detailed components of different expansion media
Origin | 2013 Huch et al. [41] | 2015 Huch et al. [42] | 2016 Broutier et al. [12] | 2018 Peng et al. [44] | 2018 Hu et al. [45] | 2020 Sorrentino et al. [13] | 2020 Gómez-Mariano et al. [14] | 2021 Hendriks et al. [46] | 2023 Hendriks et al. [93] | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mouse | Human | Mouse | Human | Mouse | Mouse | Human | Mouse | Human | Human | Human | Human | |
Type | Cholangiocyte organoid | Cholangiocyte organoid | Cholangiocyte organoid | Cholangiocyte organoid | Primary hepatocyte organoids | Hepatocyte organoids | Fetal hepatocyte organoids | Cholangiocyte organoid | Cholangiocyte organoid | Cholangiocyte organoid | Fetal hepatocyte organoids | Fetal hepatocyte organoids |
Basal medium | AdDMEM/F12 | AdDMEM/F12 | AdDMEM/F12 | AdDMEM/F12 | William’s E medium | AdDMEM/F12 | AdDMEM/F12 | AdDMEM/F12 | AdDMEM/F12 | AdDMEM/F12 | AdDMEM/F12 | AdDMEM/F12 |
HEPES (mM) | / | / | 10 | 10 | / | √ | √ | / | / | 10 | 10 | 10 |
GlutaMax | / | / | 1% | 1% | 1% | √ | √ | / | / | 1% | 1% | 1% |
Antibiotics | / | / | Penicillin–Streptomycin: 1% | Penicillin–Streptomycin: 1% | Penicillin–Streptomycin: 1% Normocin: 0.2% | √ | √ | / | / | Penicillin–Streptomycin: 1% | Penicillin–Streptomycin: 100 U/ml Primocin: 50 ug/ml | Penicillin–Streptomycin: 100 U/ml Primocin: 50 ug/ml |
Non-Essential Amino Acids | Contained in AdDMEM/F12 | Contained in AdDMEM/F12 | Contained in AdDMEM/F12 | Contained in AdDMEM/F12 | 1% | Contained in AdDMEM/F12 | Contained in AdDMEM/F12 | Contained in AdDMEM/F12 | Contained in AdDMEM/F12 | Contained in AdDMEM/F12 | Contained in AdDMEM/F12 | Contained in AdDMEM/F12 |
B-27 | √ | 1% | 2% | 2% | 2% | √ | √ | √ | √ | / | 2% | 2% |
N2 | √ | 1% | / | 1% | 1% | / | / | √ | √ | / | / | / |
N-acetylcysteine (mM) | 1.25 μM | 1.25 | 1 | 1 | 1.25 | 1.25 | 1.25 | 1.25 μM | 1.25 μM | 1 | 1.25 | 1.25 |
Rspo1 | RSPO1: 1 μg/ml or RSPO1 CMa: 10% | RSPO1 CMa: 10% | RSPO1 CMa: 5% | RSPO1 CMa: 10% | / | RSPO1 CMa: 15% | RSPO1 CMa: 15% | RSPO1: 1 μg/ml | RSPO1: 1 μg/ml | RSPO1 CMa: 5% | RSPO1 CMa: 15% | RSPO1 CMa: 15% |
Nicotinamide (mM) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 2.5 | 2.5 |
Gastrin I (nM) | 10 | 10 | 10 | 10 | / | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
EGF (ng/ml) | 50 | 50 | 50 | 50 | 25 | 50 | 50 | 50 | 50 | 50 | 50 | 50 |
HGF (ng/ml) | 50 | 25 | 50 | 25 | 50 | 25 | 50 | 50 | 25 | 50 | 50 | 50 |
FGFs (ng/ml) | FGF10: 100 | FGF10: 100 | FGF10: 100 | FGF10: 100 | / | FGF10: 50 FGF7: 50 | FGF10: 100 FGF7: 100 | FGF10: 100 | FGF10: 100 | FGF10: 100 | FGF10: 50 FGF7: 50 | FGF10: 50 FGF7: 50 |
CHIR99021 (μM) | / | / | / | / | 3 | 3 | 3 | / | / | / | 3 | 3 |
A83-01 (μM) | / | 5 | / | 5 | 1 | 1 | 2 | / | 5 | / | 1 | 1 |
Noggin (ng/ml) | 100b | 25b | 25b or noggin CMa: 5% | 25b or noggin CMa: 5% | 50c | / | / | 100b | 100b | 25b | / | / |
Wnt 3a | Wnt 3a CMab | Wnt 3a CMa: 30%b | Wnt 3a CMa: 30%b | Wnt 3a CMa: 30%b | / | / | / | Wnt 3a: 1 μg/mlb | Wnt 3a: 1 μg/mlb | Wnt 3a CMa: 30%b | / | / |
Y-27632 (μM) | / | 10b | 10b | 10b | 10b | 10b | 10b | 10b | 10b | 10b | 50b | 5-10bd |
TGFα (ng/ml) | / | / | / | / | / | / | 20 | / | / | / | 20 | 20 |
TNFα (ng/ml) | / | / | / | / | 100 | / | / | / | / | / | / | / |
FSK (μM) | / | 10 | / | 10 | / | / | / | / | 10 | / | / | / |